ZinMed commercializes a Raman + AI spectroscopy system for skin cancer screening, targeting a growing diagnostic-device market with cost advantages and domestic manufacturing capability.
The global skin-cancer diagnostic device market is worth billions USD with double-digit growth; Vietnam sees ~5,000 new cases/year.
Raman 785nm + 4-class AI (BCC/SCC/Melanoma/Benign), XAI spectral-peak traceability, running offline on-device.
Compact benchtop, made in Vietnam — far lower cost than imported systems (Verisante Aura ~hundreds of thousands USD).
Born from a VNU-level project, ~30 related publications, a proprietary 1,200-spectrum database.
Skin cancer is the start; the technology expands to diabetes, breast cancer and beyond.
Control over supply chain and cost, fit for emerging markets.
Experts in AI, spectroscopy, biomedical electronics and medicine from VNU.
ISO 13485, multi-center clinical trials, toward IEC 60825/60601.
Multi-center validation, medical-device dossier, market authorization.
Finalizing ZinRaman-D1, production line, disease expansion.
Provincial pilots, team, medical marketing.
VNU approval · optical–electronic–mechanical design
≈500 clinical + 700 simulated · Samara University · 4-class AI + XAI
Target: multi-center sensitivity/specificity validation
Toward IEC 60825/60601 · multi-disease expansion
Get in touch for the investor deck, technical documents and financial roadmap.
⚠️ Information on this page is for introduction only and is not an offer of securities or investment advice. Performance metrics are undergoing clinical validation.
← Home